Category Archives: MS Treatment

GenentechsOcrevus(ocrelizumab) continues to be the most prescribed medication to reduce inflammatory disease in people with active secondary progressive multiple sclerosis(SPMS) amongU.S. neurologists, even though NovartisMayzent(siponimod) and EMD SeronosMavenclad(cladribine) were approved in March to treat this same MS group, according to a 2019 report bySpherix Global Insights Continue reading →

Patients in England are to get easier access to Merck KGaAs multiple sclerosis drug Mavenclad after NICE dropped requirements for a special MRI scan before prescription. NICE is currently very quiet as like all government bodies it is unable to make public announcements during the purdah period before the December 12 general election. But German Merck said that NICE had issued update guidance on Mavenclad (cladribine tablets) following a fast-tracked guidance update. Continue reading →

CRANBURY, N.J.--(BUSINESS WIRE)--NeurologyLive, a multimedia platform dedicated to providing health care professionals treating neurological diseases with direct access to expert-driven, practice-changing news and insights in neurology, announces the addition of the Consortium of Multiple Sclerosis Centers (CMSC) to its Strategic Alliance Partnership (SAP) program. We are proud to be working with the CMSC, said Mike Hennessy Jr., president and CEO of MJH Life Sciences, parent company of NeurologyLive. CMSC works to improve the lives of all who have been affected by MS by bringing together a society of MS medical professionals Continue reading →

The Progressive Relapsing Multiple Sclerosis Treatment Market Perspective, Comprehensive Analysis along with Major Segments and Forecast, 2019-2025 The Progressive Relapsing Multiple Sclerosis Treatment Market Report provides key strategies followed by leading Progressive Relapsing Multiple Sclerosis Treatment industry manufactures and Sections of Market like- product specifications, volume, production value, Feasibility Analysis, Classification based on types and end user application areas with geographic growth and upcoming advancement. The Progressive Relapsing Multiple Sclerosis Treatment market report provides comprehensive outline of Invention, Industry Requirement, technology and production analysis considering major factors such as Revenue, investments and business growth. Request for sample: https://www.marketinsightsreports.com/reports/02181098761/global-progressive-relapsing-multiple-sclerosis-treatment-market-insights-forecast-to-2025/inquiry?Mode=52 Report includestop leading companies Cognosci Inc, Genzyme Corp, MedImmune LLC, VivaCell Biotechnology Espana SL Global Progressive Relapsing Multiple Sclerosis Treatment Market, By Type COG-133 GZ-402668 Inebilizumab VCE-0032 Others Global Progressive Relapsing Multiple Sclerosis Treatment Market, By Application Clinic Hopital Others Global Progressive Relapsing Multiple Sclerosis Treatment Market Segmentation by Region: North America, United States, Canada, Mexico, Asia-Pacific, China, India, Japan, South Korea, Australia, Indonesia, Malaysia, Philippines, Thailand, Vietnam, Europe, Germany, France, UK, Italy, Russia, Rest of Europe, Central & South America Get Discount on this Report: https://www.marketinsightsreports.com/reports/02181098761/global-progressive-relapsing-multiple-sclerosis-treatment-market-insights-forecast-to-2025/discount?Mode=52 In this study, the years considered to estimate the market size of Progressive Relapsing Multiple Sclerosis Treatment are as follows: History Year: 2014-2018 Base Year: 2018 Estimated Year: 2019 Forecast Year 2019 to 2025 Browse This Report: https://www.marketinsightsreports.com/reports/02181098761/global-progressive-relapsing-multiple-sclerosis-treatment-market-insights-forecast-to-2025?Mode=52 The report could be customized according to the clients specific research requirements. Continue reading →

Juliana Atieno volunteers in her local health facility as a mentor mother, providing advice and support to pregnant women newly diagnosed with HIV. She is also a passionate advocate for the survivors of gender-based violence and works to ensure that they receive the support and care they deserve, including by linking them to HIV prevention and treatment services. Continue reading →

Twenty-five years ago there were no treatments for multiple sclerosis (MS) a neurological condition that affects more than 100,000 people living in the UK. Continue reading →

A blood-cleansing process known as immunoadsorption appears to be superior to plasma exchange in treating relapses that dont respond to conventional steroid therapy in people with multiple sclerosis (MS) or clinically isolated syndrome (CIS), a study reports. Continue reading →

Researchers may have identified a way to delay the progression of multiple sclerosis (MS) by blocking a molecule that controls the entry of B cells into the brain, which results in deterioration of tissue. Results published in Science Translational Medicine show that blocking activated leukocyte cell adhesion molecule (ALCAM), which is expressed by B cells, delays the progression of the disease, according to in vitro human and in vivo mouse studies.1 These findings could result in the next generation of therapies to treat MS Continue reading →

There is a sizable gap between advancements in treatment for multiple sclerosis (MS)and their regulatory approval, which is a circumstance that necessitates increased advocacy on a global scale. This concern was a major topic of conversation recently at theXXIV World Congress of Neurology(WCN 2019) inDubai, United Arab Emirates. In recent years, especially in the past decade, there has been a surge in MS therapies that have undergone development, entered clinical trials, and obtained regulatory approval Continue reading →

TORONTO -- It's been a long, sometimes painful journey since CTVs W5 first reported on a controversial new theory about multiple sclerosis 10 years ago. Continue reading →